Tumor necrosis factor-α mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma

被引:366
作者
Nakazawa, Toru
Nakazawa, Chifuyu
Matsubara, Akihisa
Noda, Kousuke
Hisatomi, Toshio
She, Haicheng
Michaud, Norman
Hafezi-Moghadam, Ali
Miller, Joan W.
Benowitz, Larry I.
机构
[1] Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA
[2] Childrens Hosp, Neurobiol Program, Boston, MA 02115 USA
[3] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA
关键词
glaucoma; retinal ganglion cell; optic nerve; cytokines; oligodendrocyte; microglia;
D O I
10.1523/JNEUROSCI.2801-06.2006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Glaucoma is a widespread ocular disease characterized by a progressive loss of retinal ganglion cells (RGCs). Previous studies suggest that the cytokine tumor necrosis factor-α(TNF-α) may contribute to the disease process, although its role in vivo and its mechanism of action are unclear. To investigate pathophysiological mechanisms in glaucoma, we induced ocular hypertension (OH) in mice by angle closure via laser irradiation. This treatment resulted in a rapid upregulation of TNF-α, followed sequentially by microglial activation, loss of optic nerve oligodendrocytes, and delayed loss of RGCs. Intravitreal TNF-α injections in normal mice mimicked these effects. Conversely, an anti-TNF-α-neutralizing antibody or deleting the genes encoding TNF-αor its receptor, TNFR2, blocked the deleterious effects of OH. Deleting the CD11b/CD18 gene prevented microglial activation and also blocked the pathophysiological effects of OH. Thus TNF-α provides an essential, although indirect, link between OH and RGCloss in vivo. Blocking TNF-α signaling or inflammation, therefore,may be helpful in treating glaucoma. Copyright © 2006 Society for Neuroscience.
引用
收藏
页码:12633 / 12641
页数:9
相关论文
共 58 条
[31]  
LEVKOVITCHVERBI H, 2006, ARCH OPHTHALMOL-CHIC, V124, P250
[32]   Elevated Intraocular pressure and transgenic applications in the mouse [J].
Lindsey, JD ;
Weinreb, RN .
JOURNAL OF GLAUCOMA, 2005, 14 (04) :318-320
[33]   Optic nerve damage in mice with a targeted type I collagen mutation [J].
Mabuchi, F ;
Lindsey, JD ;
Aihara, M ;
Mackey, MR ;
Weinreb, RN .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (06) :1841-1845
[34]   Investigating the effect of ciliary body photodynamic therapy in a glaucoma mouse model [J].
Matsubara, Akihisa ;
Nakazawa, Toru ;
Husain, Deeba ;
Iliaki, Eirini ;
Connolly, Edward ;
Michaud, Norman A. ;
Gragoudas, Evangelos S. ;
Miller, Joan W. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (06) :2498-2507
[35]   The link between excitotoxic oligodendroglial death and demyelinating diseases [J].
Matute, C ;
Alberdi, E ;
Domercq, M ;
Pérez-Cerdá, F ;
Pérez-Samartín, A ;
Sánchez-Gómez, MV .
TRENDS IN NEUROSCIENCES, 2001, 24 (04) :224-230
[36]   A sublethal dose of TNFα potentiates kainate-induced excitotoxicity in optic nerve oligodendrocytes [J].
Miller, BA ;
Sun, F ;
Christensen, RN ;
Ferguson, AR ;
Bresnahan, JC ;
Beattie, MS .
NEUROCHEMICAL RESEARCH, 2005, 30 (6-7) :867-875
[37]   Structural features and biochemical properties of TNF-alpha converting enzyme (TACE) [J].
Moss, ML ;
Jin, SLC ;
Becherer, JD ;
Bickett, DM ;
Burkhart, W ;
Chen, WJ ;
Hassler, D ;
Leesnitzer, MT ;
McGeehan, G ;
Milla, M ;
Moyer, M ;
Rocque, W ;
Seaton, T ;
Schoenen, F ;
Warner, J ;
Willard, D .
JOURNAL OF NEUROIMMUNOLOGY, 1997, 72 (02) :127-129
[38]   TACE and other ADAM proteases as targets for drug discovery [J].
Moss, ML ;
White, JM ;
Lambert, MH ;
Andrews, RC .
DRUG DISCOVERY TODAY, 2001, 6 (08) :417-426
[39]   Neuroprotective effect of nipradilol on axotomized rat retinal ganglion cells [J].
Nakazawa, T ;
Tomita, H ;
Yamaguchi, K ;
Sato, Y ;
Shimura, M ;
Kuwahara, S ;
Tamai, M .
CURRENT EYE RESEARCH, 2002, 24 (02) :114-122
[40]  
Nakazawa T, 2002, INVEST OPHTH VIS SCI, V43, P3319